Patents by Inventor Daniel Haber

Daniel Haber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240083527
    Abstract: An alignment system for approaching a vehicle to a target object spatially spaced therefrom, including an object detection device attached to the vehicle and a coupling element, which in an end position detachably holds the target object, the object detection device being aligned in the direction of the target object and the data from the object detection device being used to generate an image in which the target object together with a guide marker can be seen during the approach of the vehicle. The guide marker is applied to at least one component of the vehicle arranged in an entry area of the coupling element.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 14, 2024
    Inventors: Mark MÜLLER, Benjamin KAUFHOLD, Steffen HABER, Stephan GITZEN, Yurtsever ENDER, Daniel JACOBS
  • Patent number: 11898209
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: February 13, 2024
    Assignee: The General Hospital Corporation
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • Publication number: 20230226039
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
    Type: Application
    Filed: August 17, 2022
    Publication date: July 20, 2023
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Publication number: 20220364185
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Application
    Filed: May 27, 2022
    Publication date: November 17, 2022
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Patent number: 11371101
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 28, 2022
    Assignee: The General Hospital Corporation
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Publication number: 20220098678
    Abstract: Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 31, 2022
    Inventors: David Tsai Ting, Daniel A. Haber, Shyamala Maheswaran, Doron Lipson
  • Patent number: 11142800
    Abstract: Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 12, 2021
    Assignee: The General Hospital Corporation
    Inventors: David Tsai Ting, Daniel A. Haber, Shyamala Maheswaran, Doron Lipson
  • Patent number: 11132725
    Abstract: Verified electronic products are created and distributed by an electronic platform, which includes a client interface, a creator interface, a decider interface, and a backer interface. An unverified product associated with a creator entity is received through the creator interface, where the unverified product comprises an electronic product having a set of clauses. A decider entity and backer entity are associated with the unverified product, which is converted to a verified product. The verified product is then added to a search engine associated with other previously verified products to define a collection of searchable verified products. Client information is obtained through the client interface and is used to identify a verified product from the collection of searchable verified products via the search engine. Based on the identified verified product, and instrument is built and is communicated to the client entity via the client interface for acceptance by the client entity.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: September 28, 2021
    Assignee: NATIONWIDE MUTUAL INSURANCE COMPANY
    Inventors: Cliff Currie, Daniel Haber, David Shackleton
  • Patent number: 11079383
    Abstract: Provided herein are assays and methods related to determining a ratio of expression levels of PSA/PSMA or determining the expression level of PSMA in circulating tumor cells for diagnosis and/or for the purpose of monitoring treatment efficacy for prostate cancers that are likely hormone resistant.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: August 3, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Daniel A. Haber, Shyamala Maheswaran, David T. Miyamoto
  • Publication number: 20210189501
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Application
    Filed: October 8, 2020
    Publication date: June 24, 2021
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • Publication number: 20210142915
    Abstract: Predictive models are built for the estimation of adverse health likelihood by identifying candidate model risk variables, constructing a model form for an outcome likelihood model that estimates the likelihood of an adverse outcome type using a group of risk variables selected from the set of candidate model risk variables and by classifying each selected risk variable into either a baseline group or a dynamic group. Additionally, predictive models are built by constructing separate baseline and dynamic outcome likelihood model forms and by fitting the constructed model forms to a training data set to produce final models to be used as scoring functions that compute a baseline outcome likelihood and a dynamic outcome likelihood for patient data that is not represented in the training data set. The predictive models can be used with alerting and attribution algorithms to predict the likelihood of an adverse outcome for individuals receiving care.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 13, 2021
    Inventors: Daniel Haber, Steven W. Rust
  • Publication number: 20210130910
    Abstract: The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: May 6, 2021
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: David T. TING, Daniel A. HABER, Shyamala MAHESWARAN
  • Patent number: 10900083
    Abstract: The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 26, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran
  • Publication number: 20210017604
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: April 21, 2020
    Publication date: January 21, 2021
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred BELL, Daniel A. HABER, Pasi Antero JANNE, Bruce E. JOHNSON, Thomas J. LYNCH, Matthew MEYERSON, Juan Guillermo PAEZ, William R. SELLERS, Jeffrey E. SETTLEMAN, Raffaella SORDELLA
  • Patent number: 10876151
    Abstract: Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: December 29, 2020
    Assignee: The General Hospital Corporation
    Inventors: Tilak K. Sundaresan, Zongli Zheng, Daniel A. Haber, Shyamala Maheswaran, A. John Iafrate
  • Patent number: 10872131
    Abstract: A method of identifying insights related to the occurrence of an adverse health outcome of interest, comprises extracting electronic clinical data associated with historical healthcare encounters. The method also comprises defining patient groups based upon similar data patterns present in the extracted electronic clinical data wherein the patient groups have varying likelihood for the adverse health outcome. Still further, the method comprises deriving hypothesized etiological explanations for why one or more patient groups have higher likelihood when compared to other patient groups. Optionally, the method comprises identifying clinical interventions that are intended to reduce the likelihood of the adverse outcome for certain patient groups.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: December 22, 2020
    Assignee: BATTELLE MEMORIAL INSTITUTE
    Inventors: Steven W. Rust, Daniel Haber
  • Patent number: 10669589
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: June 2, 2020
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Patent number: 10603314
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 31, 2020
    Assignees: The General Hospital Corporation, Wyeth LLC
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Patent number: 10596162
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 24, 2020
    Assignees: Wyeth LLC, The General Hospital Corporation
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Publication number: 20200032353
    Abstract: The present invention provides a novel method to determine the likelihood of effectiveness of a treatment in an individual affected with or at risk for developing cancer. The method involves detecting the presence or absence of Met amplification in an individual. The presence of Met amplification indicates that a Met targeting treatment is likely to be effective. Preferably, the Met targeting treatment is PHA-665752 or PF-02341066. In addition, the present methods allow for the detection of cancer in an individual, wherein the presence of Met amplification indicates that cancer is present and further that it will be treatable, namely with a Met targeting treatment.
    Type: Application
    Filed: October 9, 2019
    Publication date: January 30, 2020
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Daniel A. Haber, Gromoslaw A. Smolen